2. Novo slashes price on Wegovy

The weight-loss drug wars are heating up, with Novo Nordisk today announcing an effective price cut on Wegovy.

• The big picture: GLP-1 drugs are revolutionizing obesity treatment, but their steep price tag has prevented many people from getting them.

Driving the news: Novo is launching NovoCare Pharmacy, which will sell Wegovy for $499 per month directly to cash-paying patients who don't have insurance coverage for the treatment.

• It's a 23% price cut, AP reports.

State of play: Novo rival Eli Lilly last week announced a similar plan to sell its weight-loss drug Zepbound directly to patients for $349 per month.

• Both companies are also seeking to boost access as they face surging competition from compounding pharmacies.